Amgen Czech Republic's total assets reached CZK 261 mil at the end of 2017, down 11% compared to the previous year.
Current assets amounted to CZK 260 mil, or 99.6% of total assets while cash stood at CZK 0.283 mil at the end of 2017.
By contrast, total debt reached CZK 0 mil at the year-end, or 0% of total assets, while the firm's equity amounted to CZK 192 mil. As a result, net debt stood at CZK -0.283 mil at the end of 2017 and accounted for -0.147% of equity.
Net debt against equity is up 0.147 pp from five years ago (0%). The ratio against EBITDA increased from 0x seen in 2012 to -0.006x.
The company’s cost of funding amounted to in 2017, down 475 pp compared to the average over the last 5 years.
You can see all the company’s data at Amgen Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
